Design and discovery of some novel protease inhibitors against SARS-CoV-2 main protease by molecular docking, drug-likeness and ADME studies: An in-silico approach Discovery of novel protease inhibitors against 2019 nCoV
International Pharmacy Acta,
Vol. 4 No. 1 (2021),
SARS-CoV-2 emerges as a new curse to the life of global population. The infectivity and spreading rate of the disease makes it a pandemic with no such specific drug discovered yet. Considering the high spreading rate of the disease, there is an urgent need of selective anti-SARS-CoV-2 agent. SARS-CoV-2 main protease is an important target involved in transcription of the viral RNA, inhibition of which may lead to virucidal action. Repurposing strategy proves some antivirals to be effective against Mpro, but safety issues are of concern. To identify lead, computational approaches are the best to consider. The present study incorporates three standard anti-HIV agents Lopinavir, Ritonavir and Indinavir to undergo pharmacophore modeling. The initial modeling resulted in the selection of few test compounds considering the low RMSD as observed in Zinc database. Rest of the compounds was designed from the pharmacophoric features of the newly developed model. 20 compounds were subjected to molecular docking. The docking results showed that, compound 20 revealed the highest binding energy (-8.6 kcal/mol), which is even lesser than all the three standards. The other compounds 3, 4, 5, 11 and 19 also responded well to the docking study. These six compounds were further evaluated for their drug-likeness and ADME properties to raise the acceptance level of the lead(s). Further computational study includes the Molecular-Dynamic simulation of the compound 20, to ensure no or lesser variations throughout the simulation analysis. The above sequential computational study provides a hypothetical guideline to optimize the lead as effective anti-SARS-CoV-2 agent.
- Molecular docking
- Protease inhibitors
- Main protease
How to Cite
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol (2020) 92 (4): 401-402. doi: 10.1002/jmv.25678.
Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling Z, Jiang R. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging (2020) 47: 1275–1280. doi: 10.1007/s00259-020-04735-9
Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus (2020) 12 (3): e742. doi: 10.7759%2Fcureus.7423.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. Ateneo Parmense (2020) 91 (1): 157-160. doi: 10.23750/abm.v91i1.9397.
Sun P, Qie S, Liu Z, Ren J, Li K, Xi J (2020) Clinical characteristics of hospitalized patients with SARS‐CoV‐2 infection: a single arm meta‐analysis. J Med Virol (2020) 92 (6): 612-617. doi: 10.1002/jmv.25735.
Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19. Am J Emerg Med (2020). doi: 10.1016/j.ajem.2020.05.044
Coronavirus disease (COVID-19) Dashboard. World Health Organization (WHO), Geneva, Switzerland. https://covid19.who.int/ . Accessed 15 July 2020.
Gorbalenya AE, Baker SC, Baric R, Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. biorxiv (2020). doi: 10.1101/2020.02.07.937862.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents (2020) 55 (3): 105924. doi: 10.1016/j.ijantimicag.2020.105924.
Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model (2020) 60 (6): 3277-3286. doi: 10.1021/acs.jcim.0c00179.
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell discov (2020). doi: 10.1038/s41421-020-0153-3.
Ortega JT, Serrano ML, Pujol FH, Rangel HR. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target. EXCLI J (2020) 19: 400-409. doi: 10.17179%2Fexcli2020-1189.
Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, Kumar S, Bhattacharyya A, Kumar H, Bansal S, Medhi B. Drug targets for corona virus: A systematic review. Indian J Pharmacol (2020) 52 (1): 56-65. doi: 10.4103/ijp.IJP_115_20.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv (2020). doi: 10.1101/2020.02.26.964882.
Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci (2020) 252: 117652. doi: 10.1016/j.lfs.2020.117652.
Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today (2020) 15 (11-12): 444-450. doi: 10.1016/j.drudis.2010.03.013.
Yuriev E, Agostino M, Ramsland PA. Challenges and advances in computational docking: 2009 in review. J Mol Recognit (2011) 24 (2): 149-164. doi: 10.1002/jmr.1077.
Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mol Recognit (2013) 26 (5): 215-239. doi: 10.1002/jmr.2266.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23 (1-3): 3-25. doi: 10.1016/s0169-409x(00)00129-0.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem (2002) 45 (12): 2615-2623. doi: 10.1021/jm020017n.
Irwin JJ, Shoichet BK. ZINC− a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 45 (1): 177-182. doi: 10.1021/ci049714+
Schneidman-Duhovny D, Dror O, Inbar Y, Nussinov R, Wolfson HJ. PharmaGist: a webserver for ligand-based pharmacophore detection. Nucleic Acids Res (2008) 36: W223-228. doi: 10.1093/nar/gkn187.
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminformatics (2011) 3 (1): 33. doi: 10.1186/1758-2946-3-33
Koes DR, Camacho CJ. ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res (2012) 40 (W1): W409-414. doi: 10.1093/nar/gks378.
Panda SK, Saxena S, Gupta PS, Rana MK. Inhibitors of Plasmepsin X Plasmodium falciparum: Structure-based pharmacophore generation and molecular dynamics simulation. J Mol Liquids (2021):116851. doi: 10.1016/j.molliq.2021.116851.
DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsletter on protein crystallography (2002) 40 (1): 82-92.
Guex N, Peitsch MC. SWISS‐MODEL and the Swiss‐Pdb Viewer: an environment for comparative protein modeling. Electrophoresis (1997) 18 (15): 2714-2723. doi: 10.1002/elps.1150181505.
Van Aalten DM, Bywater R, Findlay JB, Hendlich M, Hooft RW, Vriend G. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J Computer Aid Mol Des (1996) 10 (3): 255-262. doi: 10.1007/BF00355047.
Trott O, Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking. J Comput Chem (2010) 31: 455-461. doi: 10.1002/jcc.21334.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep (2017) 7: 42717. doi: 10.1038/srep42717.
Yang, J. F., Wang, F., Chen, Y. Z., Hao, G. F., & Yang, G. F. LARMD: Integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor. Brief Bioinformatics (2019) 1-13. doi: 10.1093/bib/bbz141.
Moitessier N, Westhof E, Hanessian S. Docking of aminoglycosides to hydrated and flexible RNA. J Med Chem (2006) 49(3):1023-1033. doi:10.1021/jm0508437.
Das A, Nandi S, Das K, Banerjee S. Virtual screening of few novel Sulindac derivatives as multi-targeted agents. Drug Discov (2020) 14(33):33-43.
Fromm M F. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin Pharmacol Ther (2000) 38 (2): 69-74. doi: 10.5414/cpp38069
Potts R O and Guy R H. Predicting Skin Permeability. Pharm. Res. (1992) 9 (5): 663-69.
Hollenberg P F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev (2002) 34 (1-2): 17-35. doi: 10.1081/dmr-120001387.
Kirchmair J. Kirchmair J, Göller AH, Lang D, Kunze J, Testa B, Wilson ID, Glen RC, Schneider G. Predicting drug metabolism: experiment and/or computation? Nature Rev. Drug Discov (2015) 14 (6): 387-404. doi: 10.1038/nrd4581.
Baell J B and Holloway G A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 53 (7): 2719-2740. doi: 10.1021/jm901137j.
Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, Wyatt PG. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem (2008) 3 (3): 435-444. doi: 10.1002/cmdc.200700139.
- Abstract Viewed: 198 times
- PDF Downloaded: 96 times